On November 4, Charles River Laboratories fell 5.09% in Regular Trading, trading at $337.48 per share, with turnover of $138 million.

The move followed the company’s latest earnings release, after which trading focused on the gap between stronger profitability and still-declining revenue, amplifying short-term positioning pressure.

For the third quarter, Charles River Laboratories reported non-GAAP EPS of $3.09, above the $2.97 consensus, and revenue of $982.7 million, above the expected $960.4 million, though still below roughly $1.0 billion a year earlier. The company also raised full-year non-GAAP EPS guidance to $11.35-$11.55 from $11.15-$11.45 and narrowed its expected full-year revenue decline to 2% to 1.5%, versus the prior 3.5% to 2.5% decline. Even with several recent target-price increases from major brokerages, the latest price action suggests near-term disagreement over how much of the earnings improvement was already reflected in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)